PMID- 34151703
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20220414
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 12
DP  - 2021 Dec
TI  - Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a 
      systematic review of clinicopathological features and management.
PG  - 2845-2853
LID - 10.1080/10428194.2021.1941929 [doi]
AB  - Anaplastic lymphoma kinase-positive (ALK+) large B-cell lymphoma (LBCL) is a rare 
      CD20-negative aggressive lymphoma. Given its rarity, data on ALK + LBCL are 
      scarce and limited to case reports and small case series. Our systematic review 
      included 184 unique cases published in the literature and shows that ALK + LBCL 
      can affect individuals at any age, has a male predominance and is not associated 
      with chronic viral infections. The malignant cells express ALK, VS38c, BLIMP-1, 
      EMA, c-MYC, and BOB-1. The STAT3/STAT5, PI3K/AKT, PLCG2, and ERK pathways are 
      important in the pathophysiology of ALK + LBCL. The prognosis of ALK + LBCL is 
      poor with a 5-year survival rate of 28%. Early disease stage is associated with 
      better outcomes. ALK inhibitors and other targeted agents could be of value in 
      the treatment of ALK + LBCL. Additional research is needed to better understand, 
      diagnose and treat ALK + LBCL.
FAU - Castillo, Jorge J
AU  - Castillo JJ
AUID- ORCID: 0000-0001-9490-7532
AD  - Division of Hematologic Malignancies, Dana-Farber Cancer Institute Harvard 
      Medical School, Boston, MA, USA.
FAU - Beltran, Brady E
AU  - Beltran BE
AUID- ORCID: 0000-0003-4469-3817
AD  - Department of Oncology and Radiotherapy, Hospital Nacional Edgardo Rebagliati 
      Martins, Lima, Peru.
FAU - Malpica, Luis
AU  - Malpica L
AUID- ORCID: 0000-0002-7082-1846
AD  - Division of Hematology and Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Marques-Piubelli, Mario L
AU  - Marques-Piubelli ML
AUID- ORCID: 0000-0002-6324-2096
AD  - Department of Translational Molecular Pathology, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Miranda, Roberto N
AU  - Miranda RN
AUID- ORCID: 0000-0002-8467-5464
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20210621
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Humans
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnosis/metabolism/therapy
MH  - *Lymphoma, Large-Cell, Anaplastic
MH  - Male
MH  - Phosphatidylinositol 3-Kinases
MH  - Prognosis
MH  - Receptor Protein-Tyrosine Kinases/genetics/metabolism
OTO - NOTNLM
OT  - ALK
OT  - B-cell lymphoma
OT  - CD20-negative
EDAT- 2021/06/22 06:00
MHDA- 2022/04/15 06:00
CRDT- 2021/06/21 08:47
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2022/04/15 06:00 [medline]
PHST- 2021/06/21 08:47 [entrez]
AID - 10.1080/10428194.2021.1941929 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Dec;62(12):2845-2853. doi: 10.1080/10428194.2021.1941929. 
      Epub 2021 Jun 21.